Haemonetics Sees FY2027 Adj EPS $5.26-$5.31 vs $5.29 Est; Sees Sales $1.410B-$1.427B vs $1.394B Est

Haemonetics Corporation

Haemonetics Corporation

HAE

0.00

FISCAL 2027 GUIDANCE

The Company issued its fiscal 2027 GAAP total revenueand organic revenue growth guidance as follows:

           
  Total Company
Reported Revenue 4 - 7%
53rd week impact (~2%)
Currency impact 0 - 1%
Organic Revenue(1) 3 - 6%
Adjusted operating margin 50 – 100 bps expansion YoY
Adjusted earnings per diluted share Comparable to revenue growth
Free cash flow conversion(2) ~80%
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.